151 related articles for article (PubMed ID: 29924249)
41. Familial atypical multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and malignant melanoma.
Lynch HT; Fusaro RM; Pester J; Lynch JF
Br J Cancer; 1980 Jul; 42(1):58-70. PubMed ID: 7426330
[TBL] [Abstract][Full Text] [Related]
42. The interplay of sun damage and genetic risk in Australian multiple and single primary melanoma cases and controls.
McMeniman EK; Duffy DL; Jagirdar K; Lee KJ; Peach E; McInerney-Leo AM; De'Ambrosis B; Rayner JE; Smithers BM; Soyer HP; Sturm RA
Br J Dermatol; 2020 Aug; 183(2):357-366. PubMed ID: 31794051
[TBL] [Abstract][Full Text] [Related]
43. Acquired melanocytic nevi in childhood and familial melanoma.
Vredenborg A; Böhringer S; Boonk SE; Gruis NA; Out-Luijting C; Kukutsch NA; Bergman W
JAMA Dermatol; 2014 Jan; 150(1):35-40. PubMed ID: 24196164
[TBL] [Abstract][Full Text] [Related]
44. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
[TBL] [Abstract][Full Text] [Related]
45. Population-based analysis of prognostic factors and survival in familial melanoma.
Florell SR; Boucher KM; Garibotti G; Astle J; Kerber R; Mineau G; Wiggins C; Noyes RD; Tsodikov A; Cannon-Albright LA; Zone JJ; Samlowski WE; Leachman SA
J Clin Oncol; 2005 Oct; 23(28):7168-77. PubMed ID: 16192601
[TBL] [Abstract][Full Text] [Related]
46. Histologic features of melanoma associated with CDKN2A genotype.
Sargen MR; Kanetsky PA; Newton-Bishop J; Hayward NK; Mann GJ; Gruis NA; Tucker MA; Goldstein AM; Bianchi-Scarra G; Puig S; Elder DE
J Am Acad Dermatol; 2015 Mar; 72(3):496-507.e7. PubMed ID: 25592620
[TBL] [Abstract][Full Text] [Related]
47. Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma.
Abdel-Rahman MH; Pilarski R; Ezzat S; Sexton J; Davidorf FH
Fam Cancer; 2010 Sep; 9(3):431-8. PubMed ID: 20157784
[TBL] [Abstract][Full Text] [Related]
48. The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of
Sargen MR; Pfeiffer RM; Elder DE; Yang XR; Goldstein AM; Tucker MA
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):676-681. PubMed ID: 33811164
[TBL] [Abstract][Full Text] [Related]
49. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
[TBL] [Abstract][Full Text] [Related]
50. Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study.
Moloney FJ; Guitera P; Coates E; Haass NK; Ho K; Khoury R; O'Connell RL; Raudonikis L; Schmid H; Mann GJ; Menzies SW
JAMA Dermatol; 2014 Aug; 150(8):819-27. PubMed ID: 24964862
[TBL] [Abstract][Full Text] [Related]
51.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
52. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi.
Smith JH; Padnick-Silver L; Newlin A; Rhodes K; Rubinstein WS
Ophthalmology; 2007 Apr; 114(4):774-9. PubMed ID: 17207529
[TBL] [Abstract][Full Text] [Related]
53. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E
Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703
[TBL] [Abstract][Full Text] [Related]
54. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933
[TBL] [Abstract][Full Text] [Related]
55. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi.
Greene MH; Clark WH; Tucker MA; Kraemer KH; Elder DE; Fraser MC
Ann Intern Med; 1985 Apr; 102(4):458-65. PubMed ID: 3977193
[TBL] [Abstract][Full Text] [Related]
56. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.
Goldstein AM; Fraser MC; Struewing JP; Hussussian CJ; Ranade K; Zametkin DP; Fontaine LS; Organic SM; Dracopoli NC; Clark WH
N Engl J Med; 1995 Oct; 333(15):970-4. PubMed ID: 7666916
[TBL] [Abstract][Full Text] [Related]
57. Risk Factors Associated With First and Second Primary Melanomas in a High-Incidence Population.
Olsen CM; Pandeya N; Dusingize JC; Neale RE; MacGregor S; Law MH; Whiteman DC;
JAMA Dermatol; 2023 Jan; 159(1):37-46. PubMed ID: 36416830
[TBL] [Abstract][Full Text] [Related]
58. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
[TBL] [Abstract][Full Text] [Related]
59. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.
Thunell LK; Bivik C; Wäster P; Fredrikson M; Stjernström A; Synnerstad I; Rosdahl I; Enerbäck C
Melanoma Res; 2014 Jun; 24(3):190-7. PubMed ID: 24625390
[TBL] [Abstract][Full Text] [Related]
60. Heterogeneity of melanoma risk in families of melanoma patients.
Aitken JF; Duffy DL; Green A; Youl P; MacLennan R; Martin NG
Am J Epidemiol; 1994 Dec; 140(11):961-73. PubMed ID: 7985658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
